WO2002014343A8 - Composes analgesiques anti-inflammatoires et immunosuppresseurs - Google Patents

Composes analgesiques anti-inflammatoires et immunosuppresseurs

Info

Publication number
WO2002014343A8
WO2002014343A8 PCT/EP2001/009311 EP0109311W WO0214343A8 WO 2002014343 A8 WO2002014343 A8 WO 2002014343A8 EP 0109311 W EP0109311 W EP 0109311W WO 0214343 A8 WO0214343 A8 WO 0214343A8
Authority
WO
WIPO (PCT)
Prior art keywords
novel
treatment
antiinflammatory
derivatives
pharmaceutical compositions
Prior art date
Application number
PCT/EP2001/009311
Other languages
English (en)
Other versions
WO2002014343A1 (fr
Inventor
Dan Navolan
Brigitte Kopp
Original Assignee
Terness Peter
Dan Navolan
Brigitte Kopp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terness Peter, Dan Navolan, Brigitte Kopp filed Critical Terness Peter
Priority to AU2001282088A priority Critical patent/AU2001282088A1/en
Publication of WO2002014343A1 publication Critical patent/WO2002014343A1/fr
Publication of WO2002014343A8 publication Critical patent/WO2002014343A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une nouvelle utilisation de dérivés de bufadiénolide, tels quels ou sous la forme de compositions pharmaceutiques, à des fins d'immunomodulation, plus particulièrement, d'immunosuppression, à des fins d'action anti-inflammatoire et/ou d'action antitumorale, et particulièrement leur utilisation pour le traitement (thérapeutique et/ou prophylactique) d'affections chez les animaux à sang chaud qui sont sensibles à ces actions. L'invention concerne également l'utilisation de ces dérivés pour la fabrication d'une préparation pharmaceutique destinée au traitement d'une maladie ou d'une affection réagissant à ces actions. En outre, l'invention concerne des procédés permettant de fabriquer les compositions pharmaceutiques susmentionnées qui sont destinées à cette nouvelle utilisation. L'invention concerne des compositions pharmaceutiques contenant des stéroïdes et/ou une méthode de traitement consistant à administrer de tels stéroïdes. L'invention concerne également des nouveaux stéroïdes de ce type, des nouveaux composés pouvant être utilisés dans une méthode permettant le diagnostic ou le traitement thérapeutique du corps humain ou animal. L'invention concerne des procédés permettant de préparer ces composés, ainsi que des nouveaux produits intermédiaires utiles à la préparation de ces composés.
PCT/EP2001/009311 2000-08-17 2001-08-11 Composes analgesiques anti-inflammatoires et immunosuppresseurs WO2002014343A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001282088A AU2001282088A1 (en) 2000-08-17 2001-08-11 Immunosuppressive, antiinflammatory and analgetic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117675 2000-08-17
EP00117675.9 2000-08-17

Publications (2)

Publication Number Publication Date
WO2002014343A1 WO2002014343A1 (fr) 2002-02-21
WO2002014343A8 true WO2002014343A8 (fr) 2002-06-06

Family

ID=8169552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009311 WO2002014343A1 (fr) 2000-08-17 2001-08-11 Composes analgesiques anti-inflammatoires et immunosuppresseurs

Country Status (2)

Country Link
AU (1) AU2001282088A1 (fr)
WO (1) WO2002014343A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1971618A2 (fr) * 2006-01-09 2008-09-24 Btg International Limited Modulateurs du facteur 1 induit par l'hypoxie et utilisations associees
WO2007089688A2 (fr) 2006-01-31 2007-08-09 The University Of Toledo LIGAND Na/K-ATPase
CN101541319B (zh) 2006-10-31 2013-09-18 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
CN101177445B (zh) * 2006-11-08 2012-07-04 山东绿叶制药有限公司 蟾蜍二烯内酯类化合物及其制备方法与应用
WO2009033505A1 (fr) * 2007-09-14 2009-03-19 Unibioscreen S.A. Dérivés d'helleborine
JP2011530535A (ja) * 2008-08-07 2011-12-22 セントローズ， エルエルシー グリコシド化合物およびその医薬組成物
WO2010102673A1 (fr) * 2009-03-13 2010-09-16 Unibioscreen S.A. Hellébrine et dérivés d'hellébrigénine
BRPI0901758A2 (pt) * 2009-05-28 2011-01-25 Cristalia Prod Quimicos Farm uso de telocinobufagina como analgésico no tratamento das dores aguda e crÈnica; composição farmacêutica contendo telocinobufagina e uso da mesma
EP2477494B1 (fr) 2009-09-16 2015-11-11 The University of Toledo Ligands de na/k-atpase, antagonistes ouabaïnes, leurs essais et leurs utilisations
CN102101879B (zh) * 2009-12-16 2013-01-09 中国科学院大连化学物理研究所 一种沙蟾毒精空间异构体化合物及其制备和应用
WO2011088210A1 (fr) 2010-01-13 2011-07-21 The University Of Toledo Matériaux et méthodes concernant la sodium/potassium adénosine triphosphatase et src
CN102203112B (zh) 2010-01-15 2014-05-07 苏州润新生物科技有限公司 某些化合物、组合物及方法
EP2563803B1 (fr) * 2010-04-27 2016-03-09 Pharma Mar S.A. Lactones stéroïdes anti-cancer insaturés en position 7 (8)
WO2012103810A1 (fr) 2011-02-02 2012-08-09 Suzhou Neupharma Co., Ltd Certaines entités chimiques, compositions et procédés
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
EP3453713B1 (fr) * 2012-04-29 2021-09-08 Neupharma, Inc. Dérivés bufadiènolides substitués en position 3 par un groupement amine pour le traitement du cancer
EP4248978A3 (fr) * 2012-05-09 2023-11-08 The Hong Kong University of Science and Technology Procédé et composés pour l'inhibition du complexe mcm et leur application dans le traitement anticancéreux

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1165593B (de) * 1961-03-04 1964-03-19 Merck Ag E Verfahren zur Herstellung Schiff'scher Basen von Cardenoliden bzw. ihrer 3-Glykoside oder 3-Ester
US4175078A (en) * 1976-10-22 1979-11-20 Kharkovsky Naucho-Issledovatelsky Khimfo-Farmatsevtiches-Ky Institut Cardenolide and bufadienolide derivatives of ajmaline and process for producing same
JPH05112596A (ja) * 1991-10-20 1993-05-07 Reisa Cho ブフアリンおよびブフアジエノリドを有効成分とす医薬
JP2515074B2 (ja) * 1992-01-27 1996-07-10 学校法人昭和大学 ブファジェノリド型分化誘導剤

Also Published As

Publication number Publication date
AU2001282088A1 (en) 2002-02-25
WO2002014343A1 (fr) 2002-02-21

Similar Documents

Publication Publication Date Title
WO2002014343A8 (fr) Composes analgesiques anti-inflammatoires et immunosuppresseurs
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
WO2007049098A3 (fr) Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide
CA2332389A1 (fr) Preparations liposomales pour l'application d'agents anti-inflammatoires dans les voies respiratoires superieures et/ou l'oreille
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HK1073252A1 (en) Use of antiseptics in the manufacture of a pharmaceutical preparation for the prevention or treatment of inflammations in the interior of the human body
CA2436540A1 (fr) Composition pharmaceutique a base d'anticholinergiques et de corticosteroides
WO2004087141B1 (fr) Composition pharmaceutique comprenant un immunodepresseur a utiliser dans le traitement de maladies de la peau
EP1166778A3 (fr) Utilisation d'un sécrétagogue d'hormone de croissance pour traiter le lupus érythémateux systémique et les maladies intestinales inflammatoires
WO2007081486A3 (fr) Administration orale de defensines pour traiter des maladies intestinales
KR101782671B1 (ko) 피부 질환을 치료하는 방법
WO2002051379A3 (fr) Aerosol nasal thixotropique
WO2001012214A3 (fr) Mofetilmycophenolate associe a peg-ifn-alpha
WO1999045909A3 (fr) Inhibition de l'angiogenese
WO2002016408A3 (fr) Analogues de gpe
WO1996030016A3 (fr) Formulations de ridogrel a petites doses et leur utilisation dans le traitement de maladies intestinales inflammatoires
WO2001007418A3 (fr) Analogues de ceramide, leur procede de preparation et leur utilisation comme agents antitumoraux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP